Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Janssen Seeks MCL Indication for Imbruvica
April 1, 2016
- HPV Vaccine Makers, Govt to Face Class-Action Suit; MSD Says Plaintiffs’ Claim Unfounded
March 31, 2016
- Eisai Transfers Thrombocytopenia Drug to US Investment Firm
March 31, 2016
- Janssen Files Stelara for Crohn’s Disease
March 31, 2016
- EA Pharma to Start Up with 440 Sales Reps, Offer 24 Products
March 31, 2016
- Kyorin, Kissei to Jointly Develop, Market OAB Treatment
March 31, 2016
- Santen Gets Worldwide Rights to Ono’s FP and EP3 Dual Receptor Agonist
March 31, 2016
- Shionogi Files Japan, US NDAs for Naldemedine for Opioid-Induced Constipation
March 31, 2016
- Shionogi Says Complaint against ViiV-Related Tax Reassessment Rejected, Poised to Go to Court
March 30, 2016
- Astellas, Mitsubishi Tanabe to Share Compound Libraries
March 30, 2016
- In a Setback, FDA Rebuffs Label Expansion for Takeda’s Brintellix
March 30, 2016
- PeptiDream, Asahi Kasei Pharma Forge Research Collaboration
March 29, 2016
- Mylan Japan Offers Severance Package for 110 Sales Reps
March 29, 2016
- ASKA Shoots for Group Annual Sales of 70 Billion Yen in Five Years
March 29, 2016
- Asian PII Study Launched for Solasia’s PTCL Treatment: Meiji Seika Pharma
March 29, 2016
- Torii Looks to Ramp Up Sales in Allergen Sector, Expand Indications for Sublingual Therapies
March 28, 2016
- IP High Court Rules in Favor of Chugai in Oxarol Patent Suit
March 28, 2016
- Lilly Joins Hands with NCC on Biomarkers for Advanced Gastric Cancer
March 28, 2016
- Global PIII for Xtandi Launched for Hormone Sensitive Prostate Cancer: Astellas
March 28, 2016
- Takashi Nakamura to Be Promoted to President of Qol
March 25, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…